Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672879 · ClinicalTrials.gov registry record · Phase 2
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 259
- Enrollment target
NCT01672879: Clinical Trial Phase 2 study, sponsored by Gilead Sciences.
NCT01672879 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 259 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01672879, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 259 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH). It will consist of 2 phases: * Randomized Double-Blind Phase * Open-Label Phase (optional)
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL SIM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2012-10-29 |
| Est. Completion | 2017-01-03 |
| Phase | Phase 2 |
Why NCT01672879 stopped before completion
NCT01672879 is an interventional study that assigns participants to a tested intervention. The registered 259 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01672879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01672879 about?
NCT01672879 is a clinical study titled "Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH". The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH). It will consist of 2 phases: * Randomized Double-Blind Phase * Open-Label Phase (optional)
What is the current status of trial NCT01672879?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2012-10-29. Estimated completion is 2017-01-03.
What interventions are being tested in trial NCT01672879?
The interventions under investigation include: Placebo (BIOLOGICAL), SIM (BIOLOGICAL).
Who is sponsoring clinical trial NCT01672879?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01672879's enrollment target sits among peer trials
259 212th of 2000 higher than 1,789 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02361320 · 259 participants · NA
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
- NCT06797258 · 259 participants · NA
FlexHD® Pliable Investigation in Implant-Based Breast Reconstruction
- NCT06990425 · 259 participants · NA
CLOSM Trial: Groin Closure Using Layered Option for Suture Material
- NCT07399977 · 259 participants · NA
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI